@article{36dede4bb87441ff80b1b90c6c1d4786,
title = "The potential role of natriuretic peptide-guided management for patients hospitalized for heart failure",
abstract = "There are >1 million hospitalizations for heart failure (HF) in the United States annually. After discharge, 25% of these patients are rehospitalized within 30 days, and 30% are dead within 1 year. To date, all trials in patients with acute HF (AHF) have failed to improve post-discharge outcomes. There remains a need for an effective objective risk stratification strategy that is capable of reliably identifying patients at heightened risk for readmission and informing discharge decision making. Natriuretic peptide (NP) levels during and after AHF hospitalization can provide valuable information regarding congestion status and chronic remodeling stress. The lack of sensitivity and inter-rater reliability of physical examination, and failure to achieve dry weight in many patients before discharge, renders the use of NP to guide therapy to prevent readmission an attractive option. NP levels can be used across the spectrum of AHF care settings, ranging from the emergency department and inpatient stay to post-discharge follow-up and chronic management. This review summarizes available data and provides an expert opinion on the potential role of NPs to reduce HF readmissions.",
keywords = "Heart failure, hospitalization, natriuretic peptides, readmission",
author = "Alan Maisel and Yang Xue and Greene, {Stephen J.} and Pang, {Peter S.} and Januzzi, {James L.} and Pi{\~n}a, {Ileana L.} and Christopher Defilippi and Javed Butler",
note = "Funding Information: Alan Maisel, MD, has received research support from Alere, Abbott, BG Medicine, and Brahms; is a consultant to Alere, Critical Diagnostics, Sphingotect, BG Medicine, and EFG Diagnostics; has had speaking engagements for BG Medicine and Alere; and is a cofounder of Cardero Therapeutics and My Life Diagnostics. Yang Xue, MD, has received travel grants from Alere, Brahms, and BG Medicine. Stephen J. Greene, MD, has no potential conflicts. Peter S. Pang, MD, reports consultancies and honoraria from Janssen, Medtronic, Novartis, Otsuka, Trevena, scPharmaceuticals, Cornerstone Therapeutics, and BG Medicine; and has has received research support from Alere . James L. Januzzi, MD, has received research support from Roche , Critical Diagnostics , Siemens ; and is a consultant to Amgen, Novartis, Zensun, Critical Diagnostics, and Sphingotec. Ileana L. Pi{\~n}a, MD, MPH, has no potential conflicts. Christopher DeFilippi, MD, has received research support from Roche and Alere; is a consultant to Roche; and has received an honorarium from Siemens. Javed Butler, MD, MPH, has received research support from the National Institutes of Health , European Union , and Health Resources and Services Administration ; has participated in clinical trials supported by Amgen , Gambro , Otsuka , and Bio Control ; is a consultant to Amgen, BG Medicine, Celladon, Harvest, Gambro, Ono Pharma, Trevena, Bayer, Medtronic, Stemedica, and GE Healthcare; and has stock options with Stemedica. Publisher Copyright: {\textcopyright} 2015 Elsevier Inc. All rights reserved.",
year = "2015",
month = mar,
day = "1",
doi = "10.1016/j.cardfail.2014.11.009",
language = "English (US)",
volume = "21",
pages = "233--239",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "3",
}